Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan

Journal of Gastroenterology

Volumn 48, Issue 10, 2013, Pages 1128-1135

  Murakami, Kazunari ^a   Furuta, Takahisa ^b   Ando, Takashi ^c   Nakajima, Takeshi ^d   Inui, Yoshikatsu ^e   Oshima, Tadayuki ^f   Tomita, Toshihiko ^f   Mabe, Katsuhiro ^g   Sasaki, Makoto ^h   Suganuma, Takanori ⁱ   Nomura, Hideyuki ^j   Satoh, Kiichi ^k   Hori, Shinichiro ^l   Inoue, Syuuji ^m   Tomokane, Takeshi ^m   Kudo, Mineo ⁿ   Inaba, Tomoki ^o   Take, Susumu ^p   Ohkusa, Toshifumi ^q   Yamamoto, Shojiro ^r   Mizuno, Shigeaki ^s   Kamoshida, Toshiro ^t   Amagai, Kenji ^u   Iwamoto, Junichi ^v   Miwa, Jun ^w   Kodama, Masaaki ^a   Okimoto, Tadayoshi ^a   Kato, Mototsugu ^g   Asaka, Masahiro ^x   more..

^a OITA UNIVERSITY   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Social Insurance Kyoto Hospital   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e Inui Clinic of Internal Medicine   (Japan)

^f HYOGO COLLEGE OF MEDICINE   (Japan)

^g HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^h AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ CANCER CHEMOTHERAPY CENTER   (Japan)

^j Shin Kokura Hospital   (Japan)

^k JICHI MEDICAL UNIVERSITY   (Japan)

^l NATIONAL HOSPITAL ORGANIZATION   (Japan)

^m National Hospital Organization Kochi National Hospital   (Japan)

ⁿ SAPPORO HOKUYU HOSPITAL   (Japan)

^o KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^p Fukuwatari Municipal Hospital   (Japan)

^q JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^r UNIVERSITY OF MIYAZAKI   (Japan)

^s NIHON UNIVERSITY   (Japan)

^t Hitachi   (Japan)

^u IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^v TOKYO MEDICAL UNIVERSITY   (Japan)

^w Shinagawa ku   (Japan)

^x HOKKAIDO UNIVERSITY   (Japan)

more..

Author keywords

Drug resistance; Helicobacter pylori eradication therapy; Lansoprazole; Levofloxacin; Sitafloxacin

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; SITAFLOXACIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; JAPAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARD; TREATMENT DURATION;

AGED; AMOXICILLIN; ANTI-ULCER AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; LANSOPRAZOLE; LEVOFLOXACIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84883807676     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0731-8     Document Type: Article

References (20)

1. Uemura N, Okamoto S, Yamamoto S., Matsumura N, Yamaguchi S, Yamakido M., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345:784-9.
2. Wotherspoon AC, Doglioni C, Diss T.C., Pan L., Moschini A, de Boni M, et al Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993; 342:575-7.
3. Rimbara E, Noguchi N, Tanabe M., Kawai T, Matsumoto Y, Sasatsu M. Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001. Clin Microbiol Infect. 2005; 11:307-11.
4. Matsuhisa T, Kawai T, Masaoka T., Suzuki H, Ito M, Kawamura Y., et al. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. Helicobacter. 2006; 11:152-8.
5. Shimoyama T, Fukuda S, Mikami T., Fukushi M, Munakata A. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J Gastroenterol. 2004; 39:927-30.
6. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A., et al. Current concepts in the management of Helico-bacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002; 16:167-80.
7. Beales IL. Efficacy of Helicobacter pylori eradication therapies: a single centre observational study. BMC Gastroenterol. 2001; 1:7.
8. Gomollón F., Sicilia B, Ducóns JA, Sierra E., Revillo MJ, Ferrero M. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther. 2000; 14:1335-8.
9. Gisbert JP, Castro-Fernández M, Bermejo F, Pérez-Aisa A, Ducons J, Fernández-Bermejo M. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol. 2006; 101:243-7.
10. Rokkas T, Sechopoulos P, Robotis I., Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol. 2009; 104:21-5.
11. Sánchez J.E., Sáenz NG, Rincón MR, Martín IT, Sánchez EG, Martínez MJ. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother. 2000; 46:283-5.
12. Hongo M, Ohara S, Hirasawa Y., Abe S, Asaki S, Toyota T. Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing. Dig Dis Sci. 1992; 37:882-90.
13. Miwi H, Murai T, Sato K., Ohkura R, Yamada T, Nagahara A., et al. Comparison of the efficacy of 400 mg and 800 mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population. J Gastroenterol. 2000; 35:536-9.
14. Asaka M, Sugiyama T, Kato M., Satoh K, Kuwayama H, Fukuda Y., et al. A multicenter, double-blind study on triple therapy with lansop-razole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter. 2001; 6:254-61.
15. Miyachi H, Miki I, Aoyama N., Shirasaka D, Matsumoto Y, Toyoda M., et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter. 2006; 11:243-9.
16. Hirata Y, Ohmae T, Yanai A., Sakitani K, Hayakawa Y, Yoshida S., et al. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. Int J Antimicrob Agents. 2012; 39:352-5.
17. Matsuzaki J, Suzuki H, Nishizawa T., Hirata K, Tsugawa H, Saito Y., et al. Efficacy of sitafloxacin-based rescue therapy for Heli-cobacter pylori after failures of first- and second-line therapies. Antimicrob Agents Chemother. 2012; 56:1643-5.
18. Murakami K, Okimoto T, Kodama M., Tanahashi J, Fujioka T, Ikeda F., et al. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother. 2009; 53:3097-9.
19. Suzuki H, Nishizawa T, Muraoka H., Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helico-bacter pylori with gyrA mutation. Antimicrob Agents Chemother. 2009; 53:1720-1.
20. Yamamoto T, Takano T, Higuchi W., Nishiyama A, Taneike I, Yoshida K., et al. Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. Antimicrob Agents Chemother. 2011; 55:4261-6.